WO2001095945A3 - Prodrug compounds cleavable by thimet oligopeptidase - Google Patents

Prodrug compounds cleavable by thimet oligopeptidase Download PDF

Info

Publication number
WO2001095945A3
WO2001095945A3 PCT/US2001/018903 US0118903W WO0195945A3 WO 2001095945 A3 WO2001095945 A3 WO 2001095945A3 US 0118903 W US0118903 W US 0118903W WO 0195945 A3 WO0195945 A3 WO 0195945A3
Authority
WO
WIPO (PCT)
Prior art keywords
thimet oligopeptidase
prodrug compounds
cleavable
prodrug
methods
Prior art date
Application number
PCT/US2001/018903
Other languages
French (fr)
Other versions
WO2001095945A2 (en
Inventor
Matthew H Nieder
Vincent Dubois
Sanjeev Gangwar
Thomas J Lobl
Lesley B Pickford
Andre Trouet
Geoffrey T Yarranton
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Priority to CA2411660A priority Critical patent/CA2411660C/en
Priority to JP2002510122A priority patent/JP2004510703A/en
Priority to AU2001271301A priority patent/AU2001271301B2/en
Priority to EP01950291A priority patent/EP1294405A2/en
Priority to AU7130101A priority patent/AU7130101A/en
Publication of WO2001095945A2 publication Critical patent/WO2001095945A2/en
Publication of WO2001095945A3 publication Critical patent/WO2001095945A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavage sequences within the conjugate and methods of treating patients with prodrugs of the invention.
PCT/US2001/018903 2000-06-14 2001-06-11 Prodrug compounds cleavable by thimet oligopeptidase WO2001095945A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2411660A CA2411660C (en) 2000-06-14 2001-06-11 Enzyme-cleavable prodrug compounds
JP2002510122A JP2004510703A (en) 2000-06-14 2001-06-11 Enzyme-degradable prodrug compounds
AU2001271301A AU2001271301B2 (en) 2000-06-14 2001-06-11 Prodrug compounds cleavable by thimet oligopeptidase
EP01950291A EP1294405A2 (en) 2000-06-14 2001-06-11 Prodrug compounds cleavable by thimet oligopeptidase
AU7130101A AU7130101A (en) 2000-06-14 2001-06-11 Enzyme-cleavable prodrug compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21188700P 2000-06-14 2000-06-14
US60/211,887 2000-06-14
US29044801P 2001-05-11 2001-05-11
US60/290,448 2001-05-11

Publications (2)

Publication Number Publication Date
WO2001095945A2 WO2001095945A2 (en) 2001-12-20
WO2001095945A3 true WO2001095945A3 (en) 2002-08-15

Family

ID=26906558

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/018903 WO2001095945A2 (en) 2000-06-14 2001-06-11 Prodrug compounds cleavable by thimet oligopeptidase

Country Status (5)

Country Link
EP (1) EP1294405A2 (en)
JP (1) JP2004510703A (en)
AU (2) AU7130101A (en)
CA (1) CA2411660C (en)
WO (1) WO2001095945A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002303929B9 (en) 2001-05-31 2007-01-25 E. R. Squibb & Sons, L.L.C. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
ES2364452T3 (en) 2001-06-11 2011-09-02 Medarex, Inc. METHOD FOR DESIGNING PROFESSIONAL COMPOUNDS ACTIVATED BY CD10.
FR2858936A1 (en) * 2003-08-22 2005-02-25 Diatos New active compound precursor, useful as therapeutic or diagnostic agent or tracer, includes cleavable component that increases half-life in the circulation, attached through hydrophilic spacer
EP2097097B1 (en) 2006-12-01 2018-05-30 E. R. Squibb & Sons, L.L.C. Antibodies, in particular human antibodies, that bind cd22 and uses thereof
CL2007003622A1 (en) 2006-12-13 2009-08-07 Medarex Inc Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method.
JP2010513306A (en) 2006-12-14 2010-04-30 メダレックス インコーポレーティッド Human antibodies that bind to CD70 and uses thereof
US9662308B2 (en) 2008-02-01 2017-05-30 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg Orally bioavailable pentamidine prodrugs for the treatment of diseases
DE102008007381A1 (en) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidines and guanidines and their derivatives for the treatment of diseases
ES2624961T3 (en) 2013-03-21 2017-07-18 Sanofi-Aventis Deutschland Gmbh Synthesis of peptide products containing cyclic imide
US10087221B2 (en) 2013-03-21 2018-10-02 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
AU2021405744A1 (en) 2020-12-22 2023-08-03 Cobiores Nv Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005863A1 (en) * 1994-08-19 1996-02-29 La Region Wallonne Compounds, pharmaceutical composition and diagnostic device comprising same and their use
WO2000033888A2 (en) * 1998-12-11 2000-06-15 Coulter Pharmaceutical, Inc. Prodrug compounds and process for preparation thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005863A1 (en) * 1994-08-19 1996-02-29 La Region Wallonne Compounds, pharmaceutical composition and diagnostic device comprising same and their use
WO2000033888A2 (en) * 1998-12-11 2000-06-15 Coulter Pharmaceutical, Inc. Prodrug compounds and process for preparation thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. C. M. CAMARGO ET AL: "Structural features that make oligopeptides susceptible substrates for hydrolysis by recombinant thimet oligopeptides", BIOCHEMISTRY JOURNAL, vol. 324, 1997, pages 517 - 522, XP002200778 *
FERNANDEZ A-M ET AL: "N-SUCCINYL-(BETA-ALANYL-L-LEUCYL-L-ALANYL-L-LEUCYL)DOXORUBICIN: AN EXTRACELLULARLY TUMOR-ACTIVATED PRODRUG DEVOID OF INTRAVENOUS ACUTE TOXICITY", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, no. 22, 2001, pages 3750 - 3753, XP002905745, ISSN: 0022-2623 *
KNIGHT C G: "A QUENCHED FLUORESCENT SUBSTRATE FOR THIMET PEPTIDASE CONTAINING A NEW FLUORESCENT AMINO ACID, DL-2-AMINO-3-(7-METHOXY-4-COUMARYL)PROPIONIC ACID", BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB, vol. 274, no. 1, 15 February 1991 (1991-02-15), pages 45 - 48, XP000196075, ISSN: 0264-6021 *

Also Published As

Publication number Publication date
EP1294405A2 (en) 2003-03-26
CA2411660A1 (en) 2001-12-20
CA2411660C (en) 2011-03-01
AU2001271301B2 (en) 2006-08-31
JP2004510703A (en) 2004-04-08
WO2001095945A2 (en) 2001-12-20
AU7130101A (en) 2001-12-24

Similar Documents

Publication Publication Date Title
WO2002000263A3 (en) Tripeptide prodrug compounds
WO2002100353A3 (en) Cd10-activated prodrug compounds
WO2001095943A3 (en) Prodrug compounds with an oligopeptide having an isoleucine residue
EP1268412B8 (en) Sulphonamido-substituted bridged bicycloalkyl derivatives
WO2001062300A3 (en) Caspase activated prodrugs therapy
WO2000066175A3 (en) Conjugates as therapies for cancer and prostate diseases
WO2001095945A3 (en) Prodrug compounds cleavable by thimet oligopeptidase
WO2002007759A3 (en) Clostridial toxin derivatives and methods for treating pain
EP2261200A3 (en) Modified forms of pharmacacologically active agents and uses therefor
AU2001255850A1 (en) Catheter assembly for treating ischemic tissue
CA2426703A1 (en) Therapeutic agents and methods of use thereof for the modulation of angiogenesis
NO20024238D0 (en) Peptidase cleavable, targeted antineoplastic drugs, and their therapeutic use
EP1550456A3 (en) Use of botulinum toxin in the treatment of burn pain
WO2002013873A3 (en) P97-active agent conjugates and their methods of use
AU2265701A (en) Anti-hiv-1 conjugates for treatment of hiv disease
AU2001289308A1 (en) Targeted agents useful for diagnostic and therapeutic applications
MXPA03010761A (en) Pharmaceutical combinations.
WO2002016369A3 (en) Novel macrocycles and uses thereof
AU2001265253A1 (en) Treatment of hiv using hyperthermia
AU2002215904A1 (en) Compounds with a branched linker
AU2002226030A1 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2001024783A3 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
WO2000069255A8 (en) Anti-inflammatory therapy for inflammatory mediated infection
EP1201247A3 (en) Treatment of tumor metastases and cancer
WO2002067865A3 (en) N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2411660

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 510122

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001950291

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001271301

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001950291

Country of ref document: EP